2022
Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report
Tuan J, Ogbuagu O, Kumar D, Altice F, Fikrig M. Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report. Journal Of Medical Case Reports 2022, 16: 491. PMID: 36578087, PMCID: PMC9795945, DOI: 10.1186/s13256-022-03721-z.Peer-Reviewed Case Reports and Technical NotesConceptsAcute kidney injuryCoronavirus disease 2019Kidney injuryDisease 2019Cast nephropathyEnd-organ damageRenal biopsy findingsSpectrum of diseaseBaseline 6Gastrointestinal symptomsHospital courseBiopsy findingsCase presentationAPoor appetiteRenal failureRenal functionOral intakeUrine outputInitial diagnosisCaucasian manCase reportRhabdomyolysisNephropathyAbnormal tasteOrgan systems
2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
Spinner CD, Gottlieb RL, Criner GJ, López J, Cattelan AM, Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA 2020, 324: 1048-1057. PMID: 32821939, PMCID: PMC7442954, DOI: 10.1001/jama.2020.16349.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateAdministration, IntravenousAgedAlanineAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug Administration ScheduleFemaleHospitalizationHumansMaleMiddle AgedOdds RatioPandemicsPatient AcuityPneumonia, ViralSARS-CoV-2Treatment OutcomeConceptsStandard care groupRemdesivir groupStandard careModerate COVID-19Initiation of treatmentClinical statusCare groupDay 11Acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionModerate COVID-19 pneumoniaSyndrome coronavirus 2 infectionSevere coronavirus disease 2019Effect of remdesivirRemdesivir-treated patientsCoronavirus 2 infectionOpen-label trialPlacebo-controlled trialPrimary end pointUncertain clinical importanceCOVID-19 pneumoniaCoronavirus disease 2019COVID-19Significant differencesStatus distribution